ArticleFrontiers in immunology2021
Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Objective response to immune checkpoint inhibitor therapy inFrontiers in medicine · 2023Pooled it
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma.JAMA network open · 2024Trial
- PHAROS: turning single-cell perturbation models into target-directed drug-combination screens.bioRxiv : the preprint server for biology · 2026Article
- Integrating single-cell transcriptomics and machine learning reveals 4-aminobiphenyl exposure signatures and novel diagnostic biomarkers in bladder cancer.Discover oncology · 2025Article
- LASSO-Driven Selection of Biochemical and Clinical Markers for Primary Resistance to PD-1 Inhibitors in Metastatic Melanoma.Medicina (Kaunas, Lithuania) · 2025Article
- Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications.Scientific reports · 2025Article
- A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Spatial transcriptomics reveals prognostically LYZCancer immunology, immunotherapy : CII · 2025Article
- Article
- Prediction of immunotherapy response using mutations to cancer protein assemblies.Science advances · 2024Article
- Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.Frontiers in immunology · 2024Review
- Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.Frontiers in immunology · 2024Article
- Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.Journal of cancer research and clinical oncology · 2023Article
- SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.Aging · 2023Article
- Comprehensive Analysis of Necroptosis Landscape in Skin Cutaneous Melanoma for Appealing its Implications in Prognosis Estimation and Microenvironment Status.Journal of personalized medicine · 2023Article
- Identification and Validation ofCells · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitor (ICI) therapy dramatically prolongs melanoma survival. Currently, the identified ICI markers are sometimes ineffective. The objective of this study was to identify novel determinants of ICI efficacy. Methods: We comprehensively curated pretreatment somatic mutational profiles and clinical information from 631 melanoma patients who received blockade therapy of immune checkpoints (i.e., CTLA-4, PD-1/PD-L1, or a combination). Significantly mutated genes (SMGs), mutational signatures, and potential molecular subtypes were determined. Their association with ICI responses was assessed simultaneously. Results: We identified 27 SMGs, including four novel SMGs ( Conclusion: We uncovered several novel SMGs and re-annotated mutational signatures that are linked to immunotherapy response or resistance. In addition, an immune subtype was found to exhibit favorable prognoses. Further studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.